Istaroxime
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Istaroxime
- Accession Number
- DB06157
- Description
- Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 360.498
Monoisotopic: 360.241292898 - Chemical Formula
- C21H32N2O3
- Synonyms
- 3-((2-Aminoethoxy)imino)-5alpha-androstan-6,17-dione
- Istaroxime
- External IDs
- PST 2744
- PST-2744
- ST-2744
Pharmacology
- Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset
- Indication
Investigated for use/treatment in heart disease.
- Contraindications & Blackbox Warnings
- Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
- Pharmacodynamics
- Not Available
- Mechanism of action
Reduces the sodium-potassium adenosine triphosphatase (ATPase) activity and stimulates the sarcoplasmic calcium ATPase isoform 2 reuptake function.
Target Actions Organism USarcoplasmic/endoplasmic reticulum calcium ATPase 2 Not Available Humans USodium/potassium-transporting ATPase subunit alpha-1 Not Available Humans - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half-life
- Not Available
- Clearance
- Not Available
- Adverse Effects
- Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets
- Product Ingredients
Ingredient UNII CAS InChI Key Istaroxime hydrochloride R9SOU1JG5F 374559-48-5 AXHJYJDJXNOGNI-ROJIRLEOSA-N
Categories
- Drug Categories
- Classification
- Not classified
Chemical Identifiers
- UNII
- W40687GO3S
- CAS number
- 203737-93-3
- InChI Key
- MPYLDWFDPHRTEG-PAAYLBSLSA-N
- InChI
- InChI=1S/C21H32N2O3/c1-20-7-5-13(23-26-10-9-22)11-17(20)18(24)12-14-15-3-4-19(25)21(15,2)8-6-16(14)20/h14-17H,3-12,22H2,1-2H3/b23-13+/t14-,15-,16-,17+,20+,21-/m0/s1
- IUPAC Name
- (3aS,3bR,5aS,7E,9aR,9bS,11aS)-7-[(2-aminoethoxy)imino]-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthrene-1,5-dione
- SMILES
- C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 8017549
- ChEMBL
- CHEMBL2093999
- ZINC
- ZINC000004392967
- Wikipedia
- Istaroxime
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Heart Failure 1 2 Recruiting Treatment Shock, Cardiogenic 1 2 Unknown Status Treatment Decompensated Heart Failure 1 2 Withdrawn Treatment Heart Failure 1 1 Unknown Status Treatment Healthy Volunteers 1 1 Withdrawn Treatment Heart Failure 1 0 Withdrawn Basic Science Congestive Heart Failure (CHF) 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0174 mg/mL ALOGPS logP 2.4 ALOGPS logP 2.64 ChemAxon logS -4.3 ALOGPS pKa (Strongest Basic) 8.84 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 81.75 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 99.7 m3·mol-1 ChemAxon Polarizability 41.78 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets

Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Accelerate your drug discovery research with our ADMET & drug target dataset
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- S100 protein binding
- Specific Function
- This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen. Isoform 2 is involved in the regulati...
- Gene Name
- ATP2A2
- Uniprot ID
- P16615
- Uniprot Name
- Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
- Molecular Weight
- 114755.765 Da
References
- Mattera GG, Lo Giudice P, Loi FM, Vanoli E, Gagnol JP, Borsini F, Carminati P: Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol. 2007 Jan 22;99(2A):33A-40A. Epub 2006 Sep 18. [PubMed:17239702]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Steroid hormone binding
- Specific Function
- This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
- Gene Name
- ATP1A1
- Uniprot ID
- P05023
- Uniprot Name
- Sodium/potassium-transporting ATPase subunit alpha-1
- Molecular Weight
- 112895.01 Da
References
- Mattera GG, Lo Giudice P, Loi FM, Vanoli E, Gagnol JP, Borsini F, Carminati P: Istaroxime: a new luso-inotropic agent for heart failure. Am J Cardiol. 2007 Jan 22;99(2A):33A-40A. Epub 2006 Sep 18. [PubMed:17239702]
Drug created on March 19, 2008 16:14 / Updated on June 12, 2020 16:52